GET DAILY SIGNALSNovavax (NVAX): Analyst Price Targets Imply +37% Upside to $14
Key Takeaways
- The central $14 stock price target is the arithmetic mean of nine verified analyst price targets, rounded from roughly $13.78.
- With NVAX last trading near $10.20, reaching $14 would require an upside of roughly 37%.
- The analyst range is unusually wide, from $6 (J.P. Morgan) to $25 (Jefferies), reflecting sharp disagreement over the company's post-COVID transition.
- Supporting factors include the Sanofi partnership, milestone and royalty payments, a licensing-driven model, and a cash runway extended into 2029.
- Key risks are declining revenue, reliance on partner execution, negative stockholders' equity, and persistent cash burn.
- The Major News, Today's Price Move, Forecast, and Earnings pages offer additional detail on this ticker's developments, price action, and outlook.
Analyst Price Targets and Consensus View
Novavax, Inc. (NVAX) is a Gaithersburg, Maryland-based biotechnology company that develops and commercializes vaccines, including its Nuvaxovid COVID-19 vaccine and its Matrix-M adjuvant. Nine credible, current analyst price targets were reviewed to establish the central target. They span a very wide range of $6 to $25, and their arithmetic mean of about $13.78 rounds to a central target of $14.
The dispersion is the story. On the bullish side, Jefferies holds a $25 target (maintained in March 2026) and views Novavax as a capital-light adjuvant platform rather than merely a COVID-royalty story. Cantor Fitzgerald ($18), BTIG ($19), H.C. Wainwright ($16), and B. Riley Securities ($16, trimmed from $18 in November 2026) carry Buy ratings. On the cautious side, TD Cowen ($9, Hold), Bank of America ($8, Sell), Citigroup ($8, Sell), and J.P. Morgan ($6, Sell) emphasize shrinking revenue, cash burn, and execution risk. The mean should be read as a midpoint across genuinely divergent views, not as a guarantee. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how recent patterns align with these views.
Current Market Position and Path Toward the Target
Novavax shares closed near $10.20 on November 10, 2026, giving the company a market capitalization of roughly $1.7 billion. Reaching $14 would require an advance of about 37%, which qualifies as a substantial move. The stock's 52-week range is approximately $6.20 to $13.39.
The path would likely depend on continued execution of a licensing and royalty model built around Sanofi, which triggered a $125 million milestone payment in late 2026 when it launched a Phase 3 influenza-COVID-19 combination vaccine trial in Europe. Novavax reported third-quarter 2026 revenue of $68.3 million and a sharply narrowed net loss of $31.4 million, and management has pointed to a cash runway into 2029. Still, revenue is contracting from a 2025 peak of about $1.12 billion, and the company is not yet consistently profitable on a GAAP (generally accepted accounting principles) basis.
What Could Support a Move Toward the Target
- The Sanofi partnership provides milestone payments and potential royalties, and a combination flu-COVID product could expand a large addressable market.
- A licensing-heavy model and additional partnerships (including Pfizer and Takeda) offer capital-efficient, non-dilutive revenue.
- A cash runway into 2029 and reduced operating costs improve financial flexibility.
- Strong 2025 results demonstrated that the company can convert vaccine revenue into profit under the right conditions.
What Could Prevent the Target From Being Reached
- Revenue is forecast to decline, and the company has returned to losses after a profitable 2025.
- Negative stockholders' equity and ongoing cash burn leave a thinner balance-sheet cushion.
- Value creation depends heavily on partners hitting regulatory and commercial milestones, which carries timing risk.
- Competition from mRNA vaccine makers and uncertain demand for COVID and combination vaccines could compress royalties.
Technical Levels and Market Structure
The stock trades below its 50-day moving average near $10.61 but above its 200-day moving average near $9.34. The 52-week high near $13.39, set in early October 2026, stands as the nearest major resistance before the $14 target. Support sits around the $10 psychological level and the 200-day average near $9.34, with the 52-week low near $6.20 farther below. From what I see, these levels help frame where momentum could shift.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms vary. Investors should watch quarterly earnings and guidance, Sanofi's combination-vaccine clinical and commercial progress, milestone and royalty recognition, analyst target revisions, and any changes in partnership terms or the broader biotechnology funding environment. I’m watching this closely as partnership updates could be the next catalyst.
Exploring AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. In my view, it provides a practical way to stay on top of names like Novavax without needing to watch charts around the clock.
Final Assessment
The $14 central target is the average of nine verified analyst price targets spanning $6 to $25, and it implies a substantial gain of roughly 37% from a price near $10.20. The bull case rests on Sanofi milestones, royalties, and a capital-light licensing model, while the bear case centers on contracting revenue, cash burn, and dependence on partner execution. With such a wide analyst range, the target is best understood as a midpoint across competing narratives rather than a forecast. Investors should monitor partnership milestones, quarterly results, and analyst revisions as the key inputs to whether the shares can close the gap toward $14.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NVAX in +11.35% Uptrend, rising for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NVAX advanced for three days, in 192 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on NVAX as a result. In 61 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The 10-day RSI Indicator for NVAX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 21 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Moving Average Convergence Divergence Histogram (MACD) for NVAX turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 39 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
NVAX moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NVAX crossed bearishly below the 50-day moving average on October 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
NVAX broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NVAX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.324) is normal, around the industry mean (3.498). P/E Ratio (-7.046) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.759) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in development of novel recombinant vaccines
Industry Biotechnology
Advertisement